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Aims: To report a case of unexpectedpulmonary hypertensive crisis causedby endothelin release frommelanoma
cells after surgery for choroidal melanoma.
Main methods: A 56-year-old man suddenly developed dyspnea after resection of choroidal melanoma. Worsen-
ing hypoxia required intensive treatment, including percutaneous cardiopulmonary support, after which a series
of tests were immediately performed. The tentative diagnosis was idiopathic pulmonary arterial hypertension.
Key ﬁndings: Previous studies noted a signiﬁcant association betweenmelanoma and endothelin (ET)-1. We hy-
pothesized that a substantial amount of ET-1 had been released frommalignantmelanoma cells during resection,
thus triggering the pulmonary hypertensive crisis in our patient. The patient fully recovered after intensive treat-
ment and administration of the endothelin receptor antagonist bosentan.
Signiﬁcance: The success of bosentan treatment, along with the extremely high level of ET-1 on pathologic anal-
ysis, conﬁrmed our hypothesis regarding the increase in plasma ET-1 level.edicine, TohoUniversi
8515, Japan. Tel.: +8
icle under the CC BY-N© 2014 Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/ .0/).3Introduction
Sudden, unpredictable changes sometimes occur in patients during
and after surgery, and some of these events are not easy to explain.
Here, we describe an unexpected pulmonary hypertensive crisis that
occurred immediately after resection of ocular malignant melanoma.
Although there has been no report of pulmonary arterial hypertension
due to malignant melanoma, our hypothesis regarding the mechanism
underlying the pulmonary hypertensive crisis in this patient was con-
ﬁrmed by biochemical and pathologic ﬁndings.Case presentation
A 56-year-old man presented to our ophthalmology department for
treatment of trauma to his left eye. He had been well and had no past
history of major illness. Magnetic resonance imaging fortuitously re-
vealed an intraocular tumor, which appeared to be a choroidal melano-
ma, in his left eyeball (Fig. 1). He underwent endoresection and
developed sudden dyspnea after surgery. On physical examination, hety Ohashi
1 3 3468
C-ND license (was afebrile and had a normal blood pressure of 128/72 mm Hg; how-
ever, tachycardia of 110 beats/min and tachypnea of 36 breaths/min
were noted. Blood testing showed elevations in white blood cell count
(18,300/μl), C-reactive protein (2.4 mg/dl), and creatinine kinase (614
IU) but no evidence of lifestyle diseases (estimated glomerular ﬁltration
rate, 78 ml/min/1.73 m2; triglyceride, 118 mg/dl; low-density lipopro-
tein cholesterol, 126 mg/dl; uric acid, 6.2 mg/dl; casual blood glucose
level, 155 mg/dl; HbA1c, 5.5%). He had no abnormal ﬁndings on chest
auscultation, except for an accentuated second heart sound. A chest ra-
diograph showed dilatation of themain pulmonary artery (Fig. 2), and a
transthoracic echocardiogram revealed dilatation of the right ventricle
and right atrium. On contrast-enhanced computed tomography there
was no evidence of thrombi in the pulmonary arteries or obvious lung
diseases (Fig. 3). Hypoxia soon necessitated intratracheal intubation
and mechanical ventilation. Despite comprehensive medical treatment,
worsening hypoxia required introduction of percutaneous cardiopul-
monary support within 3 h of dyspnea onset. A Swan–Ganz catheter
wasused to obtainmore information on his condition:mean pulmonary
arterial pressure (mPAP) was 54 mm Hg and pulmonary capillary
wedge pressurewas 8mmHg. On the basis of these ﬁndings, a diagnosis
of pulmonary arterial hypertension was made. On day 3, his mPAP de-
creased to 30 mm Hg; however, it remained elevated (N25 mm Hg)
after withdrawing percutaneous cardiopulmonary support. On the
basis of previous reports describing endothelin (ET) release from ahttp://creativecommons.org/licenses/by-nc-nd/ .0/).3
Fig. 1. A T2-weighted magnetic resonance image of the head fortuitously revealed
choroidal melanoma in the patient's left eye.
Fig. 3. Axial and coronal sections of contrast-enhanced chest computed tomography im-
ages revealed no evidence of thrombi in pulmonary arteries.
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antagonist bosentan (62.5 mg/day) on day 7 because of the possibility
of ET release from choroidal melanoma cells during resection, which
we believed was responsible for the pulmonary hypertensive crisis.
Three hours after administration of bosentan, his mPAP decreased to
10 mm Hg and he became more relaxed (Fig. 4). Pathologic ﬁndings
conﬁrmed a diagnosis of malignant melanoma and revealed an ex-
tremely high level of ET-1 and the presence of ETB receptor (Fig. 5). In
addition, we conﬁrmed that the plasma concentration of ET-1 at day 1
was very high, 9.60 pg/ml (normal range, b2.3 pg/ml). It decreased to
1.31 pg/ml at day 6 and was 4.94 pg/dl at day 8 (24 h after the start of
bosentan therapy). The patient was weaned from mechanical ventila-
tion on day 13 and subsequently recovered without complications.Fig. 2. A chest radiograph shows dilatation of the main pulmonary artery.Discussion
The endothelins (ET-1, -2, and -3) are released from endothelium
and cause vasoconstriction via the ET receptors (ETA and ETB) on
smooth muscle cells. ET-1 is the most potent (Yanagisawa et al.,
1988), and increased expression of ET-1 is a primary factor in the path-
ogenesis of pulmonary arterial hypertension (PAH) (Giaid et al., 1993).
The endothelins also exert important effects on proliferation and differ-
entiation in melanocytes via a receptor-mediated signal transduction
pathway (Reid et al., 1996). We hypothesized that ET-1 released from
malignant melanoma cells during resection caused the pulmonary hy-
pertensive crisis. This was strongly supported by the presence of an el-
evated plasma ET-1 level, an extremely high ET-1 level on pathologic
analysis, and a marked reduction in mPAP after bosentan administra-
tion. Our hypothesis was also consistent with the time course of plasma
ET-1 level; the elevated plasma ET-1 level decreased to within normal
limits days later and increased again after administration of bosentan.
First, a massive amount of ET-1, which is a proliferation factor in malig-
nant melanoma, was released due to mechanical stimulation from
endoresection, a procedure in which the tumor is cut into very small
fragments and aspirated (Fig. 6). Previous reports found that the plasma
ET-1 concentration was signiﬁcantly higher in PAH patients (Stewart
et al., 1991) and was correlated with disease severity, especially that
of primary PAH (Rubens et al., 2001). In addition, a positive correlation
was observed between plasma ET-1 level and pulmonary vascular resis-
tance in secondary PAH (Razzaq et al., 2009). These previous ﬁndings
explain the very high level of plasma ET-1 and dramatic pulmonary hy-
pertensive crisis in our patient, which required expeditious mechanical
cardiac support. Second, the half-life of ET-1 and its binding to receptors
decreased plasma ET-1 to within normal limits, even though mPAP
remained elevated on day 6. A previous report found that the terminal
half-life of ET-1 was 455 ± 59 min in a three-compartment model
Fig. 4. Patient's clinical course: mPAP dropped to 10 mm Hg after bosentan administration.
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ceptors, the vasoconstricting effects of ET-1 persisted after elimination
of ET-1 from plasma (Shiba et al., 1989). Finally, plasma ET-1 level
was again elevated at 24 h after administration of bosentan, due to dis-
placement of ET-1 from ET receptors, as previously reported (Löfﬂer
et al., 1993). Although plasma ET-1 concentration does not change
after bosentan administration in healthy subjects (Weber et al., 1996),
it signiﬁcantly increases after bosentan administration in patients with
PAH (Löfﬂer et al., 1993; Hiramoto et al., 2007), peaking at 3–24 h
after bosentan administration (Hiramoto et al., 2007). In addition, the
ETB receptor has an important role in inducing melanocyteFig. 5. Histopathologic analysis of aspirated choroidal melanoma cells (stained with H&E,
×400). Left: staining with ET-1 antibody was mostly positive, as compared with negative
control (without melanin bleaching) (×400). Right: staining with ETB receptor antibody
conﬁrmed the presence of ETB receptor, as comparedwith negative control (withoutmel-
anin bleaching) (×400).
Fig. 6. During endoresection the tumor is cut into very small fragments and aspirated.differentiation, due to its relationship with ET-1 (Kikuchi et al., 1996),
and is a marker of malignant melanoma progression (Demunter et al.,
2001). Detection of the ETB receptor on pathologic analysis suggests
that choroidal melanoma in our patient had rapidly progressed in the
presence of marked ET-1 elevation.
Management of choroidal melanoma has moved away from enucle-
ation—the classic approach—and toward conservative non-enucleation
treatments, including endoresection, which is now widespread in
Europe and the United States. As this is the ﬁrst report of pulmonary hy-
pertension after endoresection, it might be useful to determine the differ-
ences between our patient and other patients treatedwith endoresection.Conﬂict of interest
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